Teva Pharmaceutical Industries (NYSE: TEVA) had a day on the stock market to remember on Wednesday. The drugmaker 's share price enjoyed a nearly 21% rise on the day, thanks mostly to a very ...

Teva Pharmaceutical Industries Ltd. stock rose 12% after the company reported stronger-than-expected third-quarter results, buoyed by robust growth in its branded drug portfolio. The Tel Aviv-based ...

Teva Pharmaceutical Industries Ltd ADR has reached a significant milestone as its stock hit a 52-week high, trading at $25.96. This achievement marks a notable recovery and growth trajectory for the ...

Teva Pharmaceutical Industries Limited’s TEVA shares have risen 21.6% in three months. Over the past few quarters, Teva has successfully launched several biosimilars and other high-value, complex ...

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) and Biolojic Design Ltd announced that Teva initiated IND-enabling studies with BD9, a dual-specific multibody targeting both TSLP (Thymic stromal ...

In the preceding three months, 5 analysts have released ratings for Teva Pharmaceutical Indus (NYSE:TEVA), presenting a wide array of perspectives from bullish to bearish. The following table ...

What Happened: A Form 4 filing with the U.S. Securities and Exchange Commission on Monday outlined that Weiss executed a sale ...

See how Teva Pharmaceutical Industries Limited's growth strategy and focus on specialty medicines are driving a turnaround.

Revenues grew by 3.4 percent to $4.48 billion from $4.33 billion year-on-year, on the back of strong growth across its brands ...

The big drugmaker unveiled its latest set of quarterly figures. Thanks to healthy rises in sales of key drugs, its revenue and profitability rose admirably. In its third quarter, Teva booked revenue ...